Toxicity from cancer therapies greater in women: study

Sex differences should be factored in when considering treatment options, researchers suggest

Women experience more symptomatic and haematologic adverse events from cancer treatments than men, especially from immunotherapy, a retrospective analysis has found.

Although between-sex differences in chemotherapy toxicity have been demonstrated in the past, the US researchers said there had been a gap in the literature regarding modern treatments.

“If confirmed by others, these findings would indicate that the sex of patients with cancer would be one variable to consider when assessing treatment risks,” said